Supplementary Fig. S4



Supplementary Fig. S4: Dysregulated ID1 expression in PDAs with a functional TGF-β pathway

A) SMAD4-restored *Kras^{G12D}; Cdkn2a$^{-/-}$; Smad4$^{-/-}$* mouse PDA cells (S4) and resistant populations selected as described in Figure 4G (S4.1) were plated in spheroid-forming conditions and treated with 2.5 μM SB505124 or 100 pM TGF-β for 7 days and counted.

B) Resistant populations with Tet-ON-*SMAD4* were selected as described in Figure 4G (S4.1). Cells were plated with or without doxycycline for 12h and then treated with 2.5 μM SB505124 or 100 pM TGF-β for 24h. Microscopy at 48h.

C) SMAD4-restored *Kras^{G12D}; Cdkn2a$^{-/-}$; Smad4$^{-/-}$* mouse PDA cells (S4) and resistant populations selected as described in Figure 4G (S4.1) were treated with 2.5 μM SB505124 or 100 pM TGF-β for 1.5 h and collected for qRT-PCR.

D) S4 and S4.1 cells were treated with 2.5 μM SB505124 or 100 pM TGF-β for 1.5 h and subjected to RNAPII ChIP-seq**.** Shown are gene track views of RNAPII tags at the *Id1* locus.

E) S4 and S4.1 cells were treated with 100 pM TGF-β or 800 pM BMP4 for the indicated times and subjected to immunoblotting for the indicated proteins.

F) Pathway signature analysis of differentially expressed genes in RNA-seq datasets from S4 and S4.1 cells.

G) mRNA expression levels of UDP glucoronosyltransferase (UGT) family members in S4 and S4.1 RNA-seq datasets.

H) GSEA analysis of the MK2206 signature in S4 and S4.1 RNA-seq datasets.